Brigid Makes - 08 Jun 2023 Form 4 Insider Report for AZIYO BIOLOGICS, INC. (ELUT)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
12 Jun 2023, 11:31:55 UTC
Prior SEC filing
16 May 2023
Next SEC filing
29 Jun 2023
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Jeffrey Hamet, Attorney-in-Fact for Brigid Makes

Key filing fact

Brigid Makes filed Form 4 for AZIYO BIOLOGICS, INC. (ELUT) on 12 Jun 2023.

Key facts

  • This page summarizes Brigid Makes's Form 4 filing for AZIYO BIOLOGICS, INC. (ELUT).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 12 Jun 2023, 11:31.

Change

  • Previous filing in this sequence was filed on 16 May 2023.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AZYO transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
$0
Shares
+25,000
Change %
Price
$0.000000
Shares after
25,000
Date
08 Jun 2023
Ownership
Direct
Underlying class
Class A Common Stock
Underlying amount
25,000
Exercise price
$2.37
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option was granted automatically under the Issuer's First Amended and Restated Non-Employee Director Compensation Policy and vests and becomes exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first annual meeting following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continuing in service on the Issuer's board of directors through the applicable vesting date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .